author-photo

Henrik Depenbrock

Eli Lilly and Company

23

Papers

486

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

Summary of EGFR-Biomarker data from the randomized, controlled phase 3 trial SQUIRE on adding Necitumumab to first-line Gemcitabine-Cisplatin (GC) for squamous Non-Small Cell Lung Cancer (sqNSCLC).

2017 Onkologie
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer

2017 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (11)
A05SQUIRE: a randomised, multicentre, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC); Subgroup efficacy and safety data for pts with epidermal growth factor receptor (EGFR)-expressing tumours

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).

2016 Onkologie
Show All
- Source
- Cite
- Save
Citations (9)
Efficacy and safety of necitumumab continuation therapy in phase 3 SQUIRE study

2015 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
103PDSUBGROUP ANALYSIS OF ELDERLY PATIENTS IN SQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF NECITUMUMAB (N) PLUS GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY VERSUS GC ALONE IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC)

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

2015
Show All
- Source
- Cite
- Save
Citations (0)
Subgroup analyses by performance status (PS) in the phase III SQUIRE study: First-line necitumumab (N) plus gemcitabine-cisplatin (GC) vs. GC in squamous non-small cell lung cancer (NSCLC).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
SQUIRE : étude multicentrique randomisée de phase III, en ouvert, évaluant gemcitabine-cisplatine (GC) plus necitumumab versus GC en première ligne de traitement du CBNPC épidermoïde (épi) de stade IV

2015 Revue Des Maladies Respiratoires
Show All
- Source
- Cite
- Save
Citations (0)
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

2015 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (95)